Related Experiment Video
Updated: Jun 19, 2026
08:49
Identification of Mediators of T-cell Receptor Signaling via the Screening of Chemical Inhibitor Libraries
Published on: January 22, 2019
Estradiol targets T cell signaling pathways in human systemic lupus
Emily Walters1, Virginia Rider, Nabih I Abdou
1Department of Biology, Pittsburg State University, Pittsburg, KS 66762, USA.
Clinical Immunology (Orlando, Fla.)
|October 2, 2009
Summary
Estradiol uniquely alters T cell signaling pathways in women with systemic lupus erythematosus (SLE). These changes in gene regulation may contribute to SLE pathogenesis and disease activity.
Area of Science:
- Immunology
- Endocrinology
- Genetics
Background:
- Systemic lupus erythematosus (SLE) disproportionately affects females, suggesting a role for sex hormones.
- Estrogen, particularly estradiol, is implicated in autoimmune disease development, but its specific molecular targets in SLE T cells are not fully understood.
Purpose of the Study:
- To identify signaling pathways in activated T cells that are uniquely regulated by estradiol in females with SLE.
- To investigate the role of estradiol-mediated gene regulation in T cell function and SLE pathogenesis.
Main Methods:
- Gene expression profiling of activated T cells from female SLE patients and healthy controls.
- Quantitative real-time polymerase chain reaction (qPCR) to measure downstream pathway genes with and without estradiol treatment.
- Analysis of interferon-alpha pathway target gene expression, including DRIP150 and IFIT1.
Main Results:
- Estradiol uniquely upregulated six T cell signaling pathways in SLE T cells, including interferon-alpha signaling.
- Significant differences in DRIP150 expression (+/- estradiol) were observed in SLE T cells (p=0.043).
- IFIT1 expression showed a bimodal pattern and moderate correlation (r=0.55) with SLE disease activity.
Conclusions:
- Estradiol significantly alters T cell signaling pathways crucial for T cell function in patients with SLE.
- Differential expression of transcriptional coactivators may mediate estrogen-dependent gene regulation in T cells, influencing SLE onset and progression.
Related Concept Videos
01:24T Cell Types and Functions
When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
01:26Signal Transduction: Overview
Cells respond to many types of information, often through receptor proteins positioned on the membrane. They respond to chemical signals, such as hormones, neurotransmitters, and other signaling molecules, initiating a series of molecular reactions to produce an appropriate response. This is called signal transduction. Cells also coordinate different responses elicited by the same signaling molecule via mediators, allowing molecular cross-talk.
Typically, signal transduction involves three...
Typically, signal transduction involves three...
01:20The JAK-STAT Signaling Pathway
Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as SH2...
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...